• Services for Regulatory ATMP Development
    Services for Regulatory ATMP Development

    Living biotherapeutics - Oncolytic viruses - AAV vectors

  • ATMP Biodistribution and Shedding Analysis
    ATMP Biodistribution and Shedding Analysis

    qPCR - CFU determination - Flow cytometry - EliSpot

  • MultiPlex miRNA Biomarker Discovery
    MultiPlex miRNA Biomarker Discovery

    Hydrogel particle-based >65-plex from small samples amounts

  • MultiPlex miRNA Clinical Profiling
    MultiPlex miRNA Clinical Profiling

    Pre-designed & custom >65-plex panels

Accelero Initiates Clinical Study to Collect Human Wound Fluid

The company is pleased to initiate its first formal clinical study at one of the breast cancer centres in Berlin, Germany. The study is entitled “Post-operative wound fluid collected from female breast cancer patients” and has been approved by the clinical ethics committee.

This is the first time Accelero has been setting up a clinical study. A Berlin-based breast cancer centre has been contracted to provide human wound fluid for bioanalytical purposes. This will enable Accelero to support clients developing therapeutics for wound healing.

Accelero Bioanalytics GmbH is a GLP certified contract research service provider for regulatory drug development and maintains genetic engineering (bio)safety level 2 laboratories in compliance with ICH GCP regulations.

The business model focuses on – but is not limited to – the development of allogenic Advanced Therapy Medicinal Products (ATMP) in a regulatory context. The team provides bioanalytical support for living biotherapeutics (human cells, microbial cells), viruses (oncolytic, adeno-associated vectors, etc) or vaccines (DNA, plasmids, etc).

For additional information on our services, please feel free to use our contact form, or send us an email to service(at)accelero-bioanalytics.com. The Accelero team will be happy to assist you.


To download the press release please click here.